Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 224

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 224
---
., Zhu, J., O’Sullivan, M., Searle, N. E., Hong, L. K., Dogruluk, T., Li, Z., Farmer, T. E., Rosas-Linhard, E., Luong, J., Lin, E., Simon, M. E., Tsao, D. S., Bosch, J. R. T., 
 Palmer, G., Gajra, A., Huynh, C., & Zhou, W. (2025). Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling. The Journal of Liquid Biopsy, 100322.            |

154

PRENATAL nature scientific reports A novel high-throughput molecular counting method with single base pair resolution enables accurate single-gene NIPT American Journal of Hematology Accurately identified all affected pregnancies as high risk at a greater than 9 in 10 risk Top 10 of 2023 award by AJHG* JME Journal of Medical Economics The cost to detect one affected pregnancy by UNITY Fetal Risk Screen was 62% lower than traditional carrier screening Genetics inMedicine 99.4% NPV and >90% sensitivity in a high risk population nature scientific reports Analytical sensitivity and specificity of >99.9% OBSTETRICS& GYNECOLOGY 100% concordance to 465 neonatal outcomes OBSTETRICS& GYNECOLOGY 100% concordance to 401 RhD neonatal outcomes ONCOLOGY CelPress Absolute quantification of cell-free DNA for prenatal genetics and oncology Clinical Lung Cancer Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC PRENATAL DIAGNOSIS Assay sensitivity of 96% and NPV of 99.8%.9-out-of 10 results were confirmed to be affected via neonatal outcomes Annals of Gynecology and Obstetrics Research 99.7% sensitivity, 99.9% specificity. 80% of patients were <35 years Johnson&Johnson A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) [AZALEA; ClinicalTrials.gov ID: NCT05912517] JACS JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS Methylated ctDNA Quantification: Noninvasive Approach to Monitoring Hepatocellular Carcinoma Burden Through